Strategy Asset Managers LLC Has $675,000 Stock Position in Axon Enterprise, Inc (NASDAQ:AXON)

Key Points

• Strategy Asset Managers LLC significantly increased its holdings in Axon Enterprise, raising its position by 245.8% in the first quarter, now owning 1,283 shares valued at approximately $675,000.
• Several other hedge funds have also boosted their investments in Axon, with Vanguard Group Inc owning the largest stake at 8,632,008 shares, valued at around $4.54 billion.
• Recent analyst reports have upgraded Axon Enterprise's stock ratings, with price targets set from $735.00 to $900.00, indicating strong market confidence in the company's performance.

Strategy Asset Managers LLC lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 245.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,283 shares of the biotechnology company's stock after buying an additional 912 shares during the quarter. Strategy Asset Managers LLC's holdings in Axon Enterprise were worth $675,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after buying an additional 185,571 shares in the last quarter. Capital World Investors raised its position in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after buying an additional 841,772 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after buying an additional 212,931 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after buying an additional 763,431 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Axon Enterprise by 19.8% in the 4th quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company's stock worth $426,083,000 after purchasing an additional 118,469 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Down 3.3%

AXON traded down $28.47 on Friday, reaching $842.50. 667,201 shares of the company traded hands, compared to its average volume of 731,927. The stock's 50 day moving average price is $774.27 and its 200-day moving average price is $665.08. Axon Enterprise, Inc has a 52-week low of $346.71 and a 52-week high of $885.91. The company has a market cap of $66.14 billion, a price-to-earnings ratio of 208.02, a PEG ratio of 93.35 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.62.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same period in the previous year, the firm posted $1.20 earnings per share. The firm's revenue was up 32.6% on a year-over-year basis. On average, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on AXON shares. Craig Hallum upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. JMP Securities boosted their target price on shares of Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 22nd. Finally, Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the stock an "overweight" rating in a report on Friday, July 11th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $837.69.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 9,905 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the sale, the president directly owned 298,809 shares of the company's stock, valued at $220,530,006.27. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Brittany Bagley sold 3,400 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the sale, the chief financial officer directly owned 131,833 shares of the company's stock, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,642 shares of company stock valued at $25,090,528 in the last three months. 4.40% of the stock is currently owned by insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.